1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Lumos Diagnostics Holdings Limited
  6. News
  7. Summary
    LDX   AU0000157091

LUMOS DIAGNOSTICS HOLDINGS LIMITED

(LDX)
  Report
Delayed Australian Stock Exchange  -  05/27 01:28:16 am EDT
0.2350 AUD   -2.08%
04/10Lumos Diagnostics Holdings Limited Announces Appoints Rob Sambursky to the Role of Chief Medical Officer
CI
04/10Lumos Diagnostics Announces Appointment of Current Executive Chair Sam Lanyon as Interim CEO
CI
03/31LUMOS DIAGNOSTICS : Notification regarding unquoted securities - LDX
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Liverpool CCG and Community Pharmacy Liverpool Launch FebriDx® Service at More Than 100 Community Pharmacies

01/12/2022 | 02:03am EDT

Point-of-Care Test Detects and Differentiates Bacterial v. Viral Infections in 10 Minutes

Today, Liverpool Clinical Commissioning Group (CCG) and Community Pharmacy Liverpool kicked off a new clinical service that will allow more than 100 pharmacies to offer a 10-minute, point-of-care test to differentiate bacterial from viral respiratory infection.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006163/en/

Now available at 100+ pharmacies across Liverpool, the FebriDx point-of-care test detects and differentiates bacterial v. viral respiratory infections in 10 minutes. The FebriDx test will be used for patients with an acute cough at pharmacies under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first. (Photo: Business Wire)

Now available at 100+ pharmacies across Liverpool, the FebriDx point-of-care test detects and differentiates bacterial v. viral respiratory infections in 10 minutes. The FebriDx test will be used for patients with an acute cough at pharmacies under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first. (Photo: Business Wire)

The test, named FebriDx®, will be used for patients with an acute cough at pharmacies across Liverpool under a new minor ailments service known as Pharmacy First, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a GP appointment first.

“It is often difficult for healthcare providers to determine if a respiratory infection is bacterial or viral without this type of rapid testing because the symptoms are nearly identical,” said Peter Johnstone, Head of Medicines Optimisation for Liverpool CCG.

“FebriDx lends itself to the Pharmacy First initiative really well – the test uses a small finger stick blood sample to differentiate a bacterial from viral acute respiratory infection in just 10 minutes, and we’re starting to offer this in local pharmacies to help ensure people get the right treatment.”

The FebriDx test has already been in use in some hospitals and GP Surgeries across the UK for three years, but this is the first time it has been used in the Merseyside region.

“Our goal is to provide patients with more convenient access to testing and treatment for acute cough under a new Patient Group Direction (PGD),” explains Matt Harvey, Chief Officer of Community Pharmacy Liverpool. “With the high volumes of patients with coughs and respiratory problems during the winter season, we see a real opportunity to bring this test into local pharmacies to help us provide treatment for patients more quickly – without the need for a GP appointment or prescription first.”

In addition to the convenience, clinical studies show that this test allows healthcare providers to rule out bacterial infections for their patients with 99% confidence, which can help reduce the unnecessary use of antibiotics and reduce antimicrobial resistance.

To learn more about this service, please visit: www.liverpoolccg.nhs.uk

About NHS Liverpool CCG

NHS Liverpool Clinical Commissioning Group (CCG) is responsible for commissioning (planning and buying) hospital and community health services for the people of Liverpool. It has a budget of around £840m a year. The CCG is made up of representatives from each of the city’s 85 GP practices, and is led by a Governing Body consisting of GPs from across the city. Visit the website at: www.liverpoolccg.nhs.uk

About Community Pharmacy Liverpool

Community Pharmacy Liverpool is Liverpool’s local pharmaceutical committee (LPC), an organisation which represents community pharmacies across the city. Visit the website at: www.liverpool-lpc.org.uk


© Business Wire 2022
All news about LUMOS DIAGNOSTICS HOLDINGS LIMITED
04/10Lumos Diagnostics Holdings Limited Announces Appoints Rob Sambursky to the Role of Chie..
CI
04/10Lumos Diagnostics Announces Appointment of Current Executive Chair Sam Lanyon as Interi..
CI
03/31LUMOS DIAGNOSTICS : Notification regarding unquoted securities - LDX
PU
02/27LUMOS DIAGNOSTICS : FY2022 Half Year Update
PU
02/27Lumos Diagnostics Announces That It Received Market Authorization for the FebriDx® Test..
CI
02/27LUMOS DIAGNOSTICS : Appendix 4D and Half Year Report
PU
02/27Lumos Diagnostics Holdings Limited Reports Earnings Results for the Half Year Ended Dec..
CI
02/15Lumos Diagnostics Names New CFO; Shares Decline 6%
MT
02/15Lumos Diagnostics Announces Appointment of Barrie Lambert as Chief Financial Officer fo..
CI
02/10Lumos Diagnostics Holdings Limited Resignation Rob Sambursky from its Board
CI
More news
Financials
Sales 2022 20,5 M 14,5 M 14,5 M
Net income 2022 -19,1 M -13,5 M -13,5 M
Net cash 2022 30,8 M 21,8 M 21,8 M
P/E ratio 2022 -1,91x
Yield 2022 -
Capitalization 35,4 M 25,1 M 25,1 M
EV / Sales 2022 0,23x
EV / Sales 2023 0,24x
Nbr of Employees -
Free-Float 56,8%
Chart LUMOS DIAGNOSTICS HOLDINGS LIMITED
Duration : Period :
Lumos Diagnostics Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,24 AUD
Average target price 0,63 AUD
Spread / Average Target 160%
EPS Revisions
Managers and Directors
Sam Lanyon Executive Chairman & Chief Executive Officer
Barrie Lambert Chief Financial Officer
Robert P. Sambursky Chief Medical Officer
Sacha Dopheide Chief Technology Officer
Jeffrey Bishop SVP-Research & Development